A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.

TerminatedOBSERVATIONAL
Enrollment

9

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

February 15, 2022

Study Completion Date

March 15, 2022

Conditions
Schizophrenia
Trial Locations (10)

Unknown

Hospital Regional de Málaga, Málaga

Hospital Son Llatzer, Palma de Mallorca

Hospital Universitario Son Espases, Palma de Mallorca

Complejo Asistencial Universitario de León, León

H. U. Salamanca, Salamanca

Complejo Asistencial de Zamora, Zamora

CHU Santiago, Santiago de Compostela

Hospital Álvaro Cunqueiro, Vigo

Hospital 12 de Octubre, Madrid

Hospital Universitario la Paz, Madrid

Sponsors
All Listed Sponsors
lead

Angelini Farmacéutica

INDUSTRY

NCT04742413 - A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study. | Biotech Hunter | Biotech Hunter